Blinklab
Blinklab is a technology company developing an AI-powered, smartphone-based tool for the early detection of autism and ADHD. Their technology aims to provide faster and more accessible at-home assessments, enabling families to pursue early intervention.
Short position
Blinklab (ASX:BB1) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 147 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. BB1 is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Blinklab (BB1) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $1.2MM (source: ASX (Markit))vs $375.6KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$7.2Mvs −$5.7M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.055T (source: Derived: trailing 12 months at year end)vs −$0.056 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- +221.5%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- −697.7%
- Net margin
- −597.9%
- FCF margin
- −624.8%
- ROE
- −50.7%
- ROA
- −47.8%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $7.9M
- Net debt / EBITDA
- n/a
- Current ratio
- 25.2×
- Interest cover
- −394.1×
- Cash dividends paid / net profit
- n/a
- Market cap
- $98.6M
- P/E
- n/a
- P/B
- 5.1×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $1.2MM (source: ASX (Markit)) | $375.6KM (source: ASX (Markit)) | $37.0KM (source: ASX (Markit)) | $0M (source: ASX (Markit)) |
| Operating income | −$8.4M | −$6.1M | −$1.8M | −$675.1K |
| EBITDA | −$6.8M | −$5.6M | −$1.7M | −$619.2K |
| EBIT | −$7.2M | −$5.7M | −$1.7M | −$675.1K |
| Interest expense | $21.4K | $9.9K | $4.5K | $1.3K |
| Pretax income | −$7.2M | −$5.7M | −$1.8M | −$676.4K |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$7.2M | −$5.7M | −$1.8M | −$676.4K |
| Net interest income | $369.3K | −$9.9K | −$4.5K | −$1.3K |
| EPS basic | −$0.055T (source: Derived: trailing 12 months at year end) | −$0.056 | n/a | −$0.007 |
| EPS diluted | −$0.055T (source: Derived: trailing 12 months at year end) | −$0.056 | n/a | −$0.007 |
| Shares | 152.9M | 124.3M | 99.2M | 99.2M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- 2026 Annual Report & Appendix 4EAnnual Results31 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report27 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results25 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- October 2025Bioshares, Australia's Independent Biotech Investment ResourceFinancial Report31 Dec 2025via crawler
- November 2025Outstanding USA Pilot Results Set the Path for 2026 FDA ClearanceFinancial Report31 Dec 2025via crawler
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Oct 2025via asx_announcements
- 2025 Annual Report & Appendix 4EAnnual Results28 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report25 Jul 2025via asx_announcements
Showing 10 of 20 reports